Axinn Represents Thermo Fisher in $7.2 Billion Acquisition of Patheon
May 17, 2017
Axinn is representing Thermo Fisher Scientific Inc. in its $7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Axinn Associates at the Antitrust Spring Meeting 2026: Sector-Specific Enforcement Trends
Axinn Viewpoints
Conspiracy Theories Newsletter, 2026 Edition
Byline Articles
Antitrust
Axinn Partners John Harkrider and Craig Minerva Win 2026 Concurrences Antitrust Writing Award
Awards & Recognitions
Antitrust
Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards
Awards & Recognitions
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
Is Any Deal Safe From Review in the EU? Implications of the “Towercast” Judgment
Podcast
Antitrust
Axinn Antitrust Insight: HSR Overhaul: Out with the New, In with the Old
Axinn Viewpoints
Antitrust
The DOJ's Whistleblower Program and Leniency
Axinn Viewpoints
Antitrust

